Read More

This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns

BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate

BMY

Read More

This Analyst Sees Durable Share Gains, Margin Expansion For Orthopedics-Focused Enovis

William Bliar has initiated coverage on Enovis Corp (NYSE: ENOV), a medical technology company focusing on the orthopedics market valued at approximately $25 billion, experiencing steady growth, especially in sub-categories such as extremities, which are growing rapidly due to

ENOV